4//SEC Filing
Costalas Stephen C 4
Accession 0001273013-08-000071
CIK 0001273013other
Filed
Dec 23, 7:00 PM ET
Accepted
Dec 24, 10:51 AM ET
Size
22.7 KB
Accession
0001273013-08-000071
Insider Transaction Report
Form 4
PHARMACOPEIA INCPCOP
Costalas Stephen C
EVP, General Counsel
Transactions
- Disposition to Issuer
Incentive Stock Option (right to buy)
2008-12-23$0.20/sh−54,239$10,848→ 0 totalExercise: $5.81From: 2006-01-03Exp: 2015-01-03→ Common Stock (54,239 underlying) - Disposition to Issuer
Incentive Stock Option (right to buy)
2008-12-23$0.20/sh−40,391$8,078→ 0 totalExercise: $3.84From: 2009-02-25Exp: 2018-02-25→ Common Stock (40,391 underlying) - Disposition to Issuer
Incentive Stock Option (right to buy)
2008-12-23$0.20/sh−9,766$1,953→ 0 totalExercise: $4.75Exp: 2016-03-01→ Common Stock (9,766 underlying) - Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2008-12-23$0.20/sh−21,484$4,297→ 0 totalExercise: $4.75Exp: 2016-03-01→ Common Stock (21,484 underlying) - Disposition to Issuer
Incentive Stock Option (right to buy)
2008-12-23$0.20/sh−16,927$3,385→ 0 totalExercise: $4.67From: 2008-02-28Exp: 2017-02-28→ Common Stock (16,927 underlying) - Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2008-12-23$0.20/sh−14,323$2,865→ 0 totalExercise: $4.67From: 2008-02-28Exp: 2017-02-28→ Common Stock (14,323 underlying) - Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2008-12-23$0.20/sh−70,761$14,152→ 0 totalExercise: $5.81From: 2006-01-03Exp: 2015-01-03→ Common Stock (70,761 underlying) - Disposition to Issuer
Common Stock
2008-12-23−66,006.97→ 0 total - Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2008-12-23$0.20/sh−39,609$7,922→ 0 totalExercise: $3.84From: 2009-02-25Exp: 2018-02-25→ Common Stock (39,609 underlying)
Footnotes (2)
- [F1]Disposed of pursuant to merger agreement between Pharmacopeia, Inc. ("Pharmacopeia"), Ligand Pharmaceuticals Incorporated ("Ligand") , Margaux Acquisition Corp., a wholly-owned subsidiary of Ligand, and Latour Acquisition, LLC, a wholly-owned subsidiary of Ligand, in exchange for approximately 39,505.17 shares of Ligand common stock having a market value of $2.58 per share on the effective date of the merger and $20,426.16 in cash, without interest. In addition, the reporting person received one contingent value right ("CVR") for each share of the Pharmacopeia common stock disposed of in the merger by the reporting person. The CVRs provide each holder the right to receive approximately $0.50 per share if Ligand enters into a license, sale, development, marketing or option agreement with respect to certain product candidates (other than any agreement with Bristol-Myers Squibb Company or any of its affiliates) on or prior to December 31, 2011.
- [F2]This option was canceled in connection with Pharmacopeia's offer to purchase all outstanding options, whether vested or unvested, to purchase shares of Pharmacopeia common stock, par value $0.01 per share, which was consummated on December 23, 2008. The reporting person received a cash payment of $0.20 per share of common stock issuable upon exercise of each such option.
Documents
Issuer
PHARMACOPEIA INC
CIK 0001273013
Entity typeother
Related Parties
1- filerCIK 0001313392
Filing Metadata
- Form type
- 4
- Filed
- Dec 23, 7:00 PM ET
- Accepted
- Dec 24, 10:51 AM ET
- Size
- 22.7 KB